Psychedelic medicine has spent the past decade developing clinical evidence almost exclusively in adults. Adolescents have largely remained outside the field.
That is now starting to change.
A Phase II clinical trial in Europe has been authorised to investigate MDMA-assisted therapy in 16 to 18-year-olds with treatment-resistant PTSD. Sponsored by Amsterdam UMC, the study will enrol just 12 participants and is primarily designed to assess safety and feasibility.
The small size of the trial reflects where the research currently stands. Before larger studies can be contemplated, researchers need to establish whether this type of treatment can be delivered safely to adolescents and how the therapeutic model should be adapted for a younger population.
Most of the evidence behind psychedelic-assisted therapies has been generated in adults. MDMA-assisted therapy has been studied extensively for PTSD, while psilocybin has produced encouraging results in conditions including treatment-resistant depression. Those findings cannot simply be assumed to apply to adolescents.
Mental health disorders commonly emerge during adolescence, and young people with severe or treatment-resistant conditions can face limited treatment options. Whether psychedelic-assisted therapies could eventually provide another option is a question that has received relatively little clinical investigation.
MDMA is currently further ahead than psilocybin.
Its established adult research base, particularly in PTSD, provides a starting point for investigating whether the therapy could have a role in older adolescents with severe and treatment-resistant illness. The European trial is an early attempt to answer that question under controlled clinical conditions.
Psilocybin remains further back. While research into psilocybin-assisted therapy for depression has expanded rapidly in adults, there is not yet a comparable body of clinical evidence for its use in adolescents.
Australia is also a long way from routine psychedelic treatment for young people.
The Therapeutic Goods Administration allows authorised psychiatrists to access MDMA for PTSD and psilocybin for treatment-resistant depression through the Authorised Prescriber framework. That pathway applies to adults and does not establish an adolescent treatment model.
There are also practical and ethical questions that cannot be answered by adult trials alone. Research involving adolescents needs to consider the developing brain, consent and involvement of parents or guardians, psychological support, screening criteria and longer-term follow-up.
Those issues make paediatric research more complicated, but they also make it necessary if the field is ever going to establish whether these therapies are appropriate for younger patients.
There is a reasonable argument for caution. Psychedelic-assisted therapy remains an emerging area of medicine, and the risks and benefits for adolescents are not yet understood.
There is also a case for studying the question rather than leaving it unanswered.
If psychedelic therapies eventually become established treatments for adults, clinicians will inevitably encounter younger patients with similarly serious and treatment-resistant conditions. Adult data may provide useful guidance, but it will not tell researchers everything they need to know about treating a developing population.
The European MDMA trial is therefore not evidence that psychedelic therapy is ready for adolescents. It is an attempt to establish whether the treatment can be studied safely in this age group in the first place.
For a field that has spent years generating evidence in adults, that is a meaningful shift.
The question is no longer simply whether psychedelic-assisted therapies can work in adults. Researchers are beginning to investigate whether there could eventually be a place for them earlier in life.
For now, there is no answer. The evidence has to come first.
